PROTAC BRD9-binding moiety 5

Cat. No.:	HY-143270
CAS No.:	893633-37-9
Molecular Formula:	$C_{19}H_{18}N_6O$
Molecular Weight:	346.39
Target:	Ligands for Target Protein for PROTAC; Epigenetic Reader Domain
Pathway:	PROTAC; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PROTAC BRD9-binding moiety 5 is a selective BRD9 binder with an IC_{50} value of 4.20 μM, can be used for the synthesis of PROTACs. PROTAC BRD9-binding moiety 5 has antiproliferative activity against cancer cells[1].
IC_{50} & Target	BRD9 4.2 μM (IC_{50})
In Vitro	PROTAC BRD9-binding moiety 5 (compound 7) (0-250 μM; 48h) has antiproliferative activity against Jurkat, MDA-MB-231, A375 and HCT-116[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay[1]

Cell Line:	Jurkat, MDA-MB-231, A375 and HCT-116
Concentration:	0-250 μM
Incubation Time:	48h
Result:	Exhibited antiproliferative activity against Jurkat, MDA-MB-231, A375 and HCT-116 with IC_{50}s of 77 ± 7 μM, 125 ± 8 μM, 133 ± 5 μM and 145 ± 3 μM.

REFERENCES

[1]. Pierri M, et al. Introducing structure-based three-dimensional pharmacophore models for accelerating the discovery of selective BRD9 binders. Bioorg Chem. 2022 Jan;118:105480.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA